The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
Apr 30, 2025•about 1 year ago
Contract Type
partnership
San DiegoBiotechnologyHealth Care
Description
Creyon Bio, Inc. has announced a global licensing and multi-target research collaboration with Eli Lilly and Company focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide therapies for a broad range of diseases. The collaboration aims to leverage Creyon's AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly's named targets to make therapies safer and more effective for patients with rare and common diseases.
Company Information
Company
Creyon Bio
Location
San Diego, California, United States
About
Creyon Bio is a biotechnology company focused on developing innovative therapeutic solutions. They are committed to advancing health and wellness through cutting-edge research and development. The company aims to address critical needs in the medical field.
San DiegoBiotechnologyHealth Care